AMENDMENTS TO THE CLAIMS

1. (Currently amended) A pharmaceutical composition suitable for oral administration in the form of a homogeneous solution which on exposure to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 microns, the solution comprising: (a) a pharmaceutically effective amount of a cyclosporin, (b) a carrier medium comprising a mixture of mono- and diesters of propylene glycol with fatty acids having from 8 to 10 carbon atoms or with mixtures of such fatty acids, wherein the monoester makes up less than between 50 and 60 mol % of the mixture, and (c) a non-ionic surfactant having a hydrophilic lipophilic balance (HLB) greater than 10.

2 - 3. (Canceled)

- 4. (Currently amended)A pharmaceutical composition according to claim [[2]] 1, wherein the cyclosporin is 5 to 20% by weight of the composition, the carrier medium is 35 to 60% by weight of the composition, and the non-ionic surfactant is 20 to 50% by weight of the composition.
- 5. (Currently amended) A pharmaceutical composition according to claim [[2]] 1, wherein the cyclosporin is 15 to 20% by weight of the composition, the carrier medium is 40 to 55% by weight of the composition, and the non-ionic surfactant is 30 to 40% by weight of the composition.

- 6. (Original) A pharmaceutical composition according to claim 1, wherein said carrier medium consists of a mixture of mono- and diesters of propylene glycol with capric and caprylic acids.
- 7. (Original) A pharmaceutical composition according to claim 1, wherein said carrier medium consists of a mixture of mono- and diesters of propylene glycol with caprylic acid.
- 8. (Original) A pharmaceutical composition according to claim 1, wherein the cyclosporin is 1 to 25% by weight of the composition, the carrier medium is 20 to 80% by weight of the composition, and the non-ionic surfactant is 5 to 60% by weight of the composition.
- 9. (Original) A pharmaceutical composition according to claim 1, wherein the non-ionic surfactant is selected from the group consisting of: polyoxyethyled products of hydrogenated vegetable oil, polyethoxylated castor oil, polyethoxylated hydrogenated castor oil, polyoxyethylenesorbitan-fatty acid ester, polyoxyethylene castor oil derivative, and mixtures thereof.
- 10. (Original) A pharmaceutical composition, according to claim 9, wherein the non-ionic surfactant is selected from the group consisting of polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene (20) sorbitan monooleate, PEG-30 hydrogenated castor oil, PEG-40 hydrogenated castor oil, PEG-50 hydrogenated castor oil, PEG-60

Docket No.: M0025.0293

hydrogenated castor oil, polyoxyethylene 40 castor oil, polyoxyethylene 60 castor oil, polyoxyethylene 35 castor oil, and mixtures thereof.

- 11. (Original) A pharmaceutical composition according to claim 1, further comprising an antioxidant.
- 12. (Original) A pharmaceutical composition according to claim 11, wherein the antioxidant is selected from the group consisting of BHA, BHT, and alpha-tocopherol.
- 13. (Original) A pharmaceutical composition according to claim 1, wherein the cyclosporin is Cyclosporin A.
- 14. (Original) A pharmaceutical composition according to claim 1, wherein the cyclosporin is 5 to 400 mg and is 1 to 25% by weight of the composition, the carrier medium is 20 to 80% by weight of the composition and is a mixture of mono- and diesters of propylene glycol with capric and caprylic acids or a mixture of mono- and diesters of propylene glycol with capric and caprylic acids in which the monoester is between 50 and 60 mol % of the mixture of mono- and diesters, the non-ionic surfactant is 5 to 60% by weight of the composition and has a HLB greater than 12, and the composition contains antioxidant in an amount of from 0.01% to 2% by weight of the composition.
- 15. (Original) A pharmaceutical composition according to claim 1, wherein the cyclosporin is 20 to 200 mg of Cyclosporin A and is 15 to 20% by weight of the composition, the carrier medium is 40 to 55% by weight of the

After Final Office Action of April 16, 2007

composition and is a mixture of mono- and diesters of propylene glycol with capric and caprylic acids or a mixture of mono- and diesters of propylene glycol with capric and caprylic acids in which the monoester is between 50 and 60 mol % of the mixture of mono-and diesters, the non-ionic surfactant is 30 to 40% by weight of the composition and has a HLB greater than 14, and the composition contains antioxidant in an amount of from 0.5% to 1% by weight of the composition.

- 16. (Original) A pharmaceutical composition according to claim 15, formulated as a drinking solution.
- 17. (Original) A pharmaceutical composition according to claim 1, formulated as a drinking solution.
- 18. (Original) A pharmaceutical composition according to claim 1 formulated as a hard or soft capsule.
- 19. (Original) A pharmaceutical composition according to claim 16 contained within a soft gelatine capsule.
- 20. (Original) A pharmaceutical composition according to claim 1 contained within a soft gelatine capsule.